White Paper

Health leaders, particularly those in low- and middle-income countries (LMICs), face a structural gap between the rapid pace of health innovation and the ability of their countries to anticipate, prioritize, finance, and introduce new products effectively and efficiently. Decisions about adopting devices, diagnostics, therapeutics, and vaccines are often made reactively, with limited visibility into product supply (new emerging products, pipelines, costs, regulatory timelines, delivery requirements), health system capacity, and local context, including demand. Yet such visibility is key to country-led improved health product prioritization and introduction decisions. This paper, developed by the ALIGN Consortium, announces a tool to address the gap between the possible pipeline and realized rollout of health products. ALIGN Market Intelligence Hub is a decision-support tool designed to transform fragmented data on health products into actionable prioritization and…